Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3

Coronary Thrombosis Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02591264
• Other study ID #: 90-14-HYMC
• Status: Not yet recruiting
• Phase: N/A
• First received: October 28, 2015
• Last updated: October 28, 2015
• Start date: November 2015
• Est. completion date: November 2016

Study information

• Verified date: October 2015
• Source: Hillel Yaffe Medical Center
• Contact: Rami Abu Fanne, MD, PhD
• Phone: 972-50-3573694
• Email: ramia[@]hadassah.org.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The aim of this study is to determine the role of human neutrophil peptide-1 to 3 in the occurrence of periprocedural myocardial infarction.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Troponin negative patients

• Stable angina

• Unstable angina

• Positive screening tests

Exclusion Criteria:

• Troponin positive

• Technical failure of procedure

• Hemodynamic unstability

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Thrombosis

Intervention

Other:
• Blood sample
Blood sample drawn from participants for analysis of neutrophil peptide level

Locations

Country	Name	City	State
Israel	Hillel Yaffe Medical Center	Hadera

Sponsors (1)

Lead Sponsor	Collaborator
Hillel Yaffe Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Human Neutrophil Peptide Level	Laboratory analysis and measurement of Human Neutrophil Peptide-1 to 3 levels	Two hours	No